Phase 2 trial to evaluate SUN-627, a potent, highly-selective, brain-penetrant, oral allosteric TYK2 inhibitor, in people with progressive forms of MS
SUN-627 demonstrated favorable safety, tolerability, and pharmacokinetics for oral, once-daily dosing in healthy volunteers
Randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy in a robust, two-part study
Electra Therapeutics, Inc. today announced the pricing of its upsized initial public offering of 23,333,334 shares of common stock at a price to the public of $15.00 per share.
Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the pricing of its upsized initial public offering of 19,200,000 shares of common stock at a price to the public of $18.00 per share.
$2.5 million grant supports clinical trial activation and patient screening efforts for precision medicine approach targeting LRRK2-driven Parkinson’s disease at four clinical sites in Israel
Targeting clinically validated pathways to enable patients to achieve freedom from migraine
Recludix today announced preclinical data for REX-8756, an oral, potent and selective STAT6 inhibitor, is being presented at two upcoming scientific congresses.
Star Therapeutics to receive $1.25 billion upfront, with up to $750 million in additional payments upon achievement of sales milestones
Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36
